Exchange: NYSE·Updated 07:30 PM EDT
News
all
press releases
Jury Awards 10x Genomics Millions in Patent Lawsuit Against Qiagen Unit
10x Genomics won a $4.8 million patent infringement lawsuit against Qiagen subsidiary Parse Biosciences, prompting plans for an injunction.read more...
Benzinga
More News
TXG Stock Down Despite Patent Verdict Win Against Parse Biosciences
10x Genomics wins a $4.8M patent verdict against Parse, strengthening its IP position as it seeks added damages and a U.S. injunction.
Zacks
10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences
10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences 10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences PR Newswire PLEASANTON, Calif., Aug. 28, 2026 Jury finds Parse willfully infringed Scale Biosciences' patents and rejects Parse's invalidity...
PR Newswire
QIAGEN Launches QIAsymphony Connect for Automated Clinical Nucleic Acid Extraction
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the commercial launch of QIAsymphony Connect, an IVD-compliant platform for automated clinical nucleic acid extraction. Building on the trusted QIAsymphony platform, with more than 3,300 cumulative placements worldwide...
Business Wire
Qiagen Appoints Jonathan Pratt To Succeed Thierry Bernard As CEO
(RTTNews) - QIAGEN N.V. (QGEN) announced Monday that Jonathan Pratt has been appointed Chief Executive Officer, effective September 1, 2026. He brings to QIAGEN more than 25 years of international leadership experience across life sciences, laboratory technologies and healthcare...
Nasdaq News: Markets
QIAGEN Appoints Jonathan M. Pratt as Chief Executive Officer
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Jonathan M. Pratt has been appointed Chief Executive Officer, effective September 1, 2026. He brings to QIAGEN more than 25 years of international leadership experience across life sciences, laboratory technologies and...
Business Wire
Bio-Rad Gains 19.1% in the Past Month: Can Its Momentum Keep Building?
BIO's 19.1% monthly rally is backed by digital PCR gains and steadier diagnostics, but weak Life Science demand and a rich valuation loom.
Zacks
Qiagen (QGEN) Q2 2026 Earnings Call Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
Qiagen Breaks Above 200-Day Moving Average - Bullish for QGEN
In trading on Monday, shares of Qiagen NV (Symbol: QGEN) crossed above their 200 day moving average of $42.98, changing hands as high as $44.41 per share. Qiagen NV shares are currently trading up about 3.6% on the day. The chart below shows the one year performance of QGEN sh...
Nasdaq News: Markets
QIAGEN Receives U.S. FDA Clearance for First QIAstat-Dx Bloodstream Infection Panel
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has cleared the QIAstat-Dx BCID GPF Plus AMR Panel, the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance. The clearance expands QIAGENs U.S. syndromic...
Business Wire

Advertisement|Remove ads.